{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:11:41Z","timestamp":1775715101653,"version":"3.50.1"},"reference-count":253,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007434","name":"Suzuken Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006452","name":"University of Miyazaki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008593","name":"Japan Foundation for Aging and Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.pharmthera.2022.108187","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T19:25:13Z","timestamp":1649964313000},"page":"108187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Regulation of feeding and therapeutic application of bioactive peptides"],"prefix":"10.1016","volume":"239","author":[{"given":"Hiroaki","family":"Ueno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2022.108187_bb0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cmet.2015.01.006","article-title":"Suppression of insulin production and secretion by a decretin hormone","volume":"21","author":"Alfa","year":"2015","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0015","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1111\/dom.14536","article-title":"Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials","volume":"23","author":"Araki","year":"2021","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: A step-by-step approach","volume":"42","author":"Araujo-Vilar","year":"2019","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0025","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0196-9781(82)90164-4","article-title":"The stability and metabolism of intravenously administered neurotensin in the rat","volume":"3","author":"Aronin","year":"1982","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0030","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/gut.52.7.947","article-title":"Antagonism of ghrelin receptor reduces food intake and body weight gain in mice","volume":"52","author":"Asakawa","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0035","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0040","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0045","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-18-0596","article-title":"The melanocortin pathway and control of appetite-progress and therapeutic implications","volume":"241","author":"Baldini","year":"2019","journal-title":"Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0050","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1210\/jc.2017-02751","article-title":"Increased plasma proneurotensin levels identify NAFLD in adults with and without type 2 diabetes","volume":"103","author":"Barchetta","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0055","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41366-020-00703-3","article-title":"Circulating LEAP-2 is associated with puberty in girls","volume":"45","author":"Barja-Fernandez","year":"2021","journal-title":"International Journal of Obesity"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0060","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/nature01388","article-title":"STAT3 signalling is required for leptin regulation of energy balance but not reproduction","volume":"421","author":"Bates","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molmet.2019.01.011","article-title":"The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice","volume":"22","author":"Beaudry","year":"2019","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0070","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0196-9781(88)90113-1","article-title":"Anorectic effect of calcitonin, neurotensin and bombesin infused in the area of the rostral part of the nucleus of the tractus solitarius in the rat","volume":"9","author":"de Beaurepaire","year":"1988","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0075","doi-asserted-by":"crossref","first-page":"E545","DOI":"10.1152\/ajpendo.00255.2009","article-title":"Appetite-modifying actions of pro-neuromedin U-derived peptides","volume":"297","author":"Bechtold","year":"2009","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF02427284","article-title":"Direct metabolic effects of gastric inhibitory polypeptide (GIP): Dissociation at physiological levels of effects on insulin-stimulated fatty acid and glucose incorporation in rat adipose tissue","volume":"29","author":"Beck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0085","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuroscience.2013.11.023","article-title":"Neuromedin U receptor 2 knockdown in the paraventricular nucleus modifies behavioral responses to obesogenic high-fat food and leads to increased body weight","volume":"258","author":"Benzon","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0090","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2337\/dc19-0578","article-title":"No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon-like peptide 1 receptor agonist in men with type 2 diabetes","volume":"43","author":"Bergmann","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0095","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00125-018-4810-0","article-title":"Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight\/obese individuals: A randomised, crossover study","volume":"62","author":"Bergmann","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0100","first-page":"R501","article-title":"Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo","volume":"261","author":"Billington","year":"1991","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0105","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/262607a0","article-title":"Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin","volume":"262","author":"Bissette","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0110","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00023210-200721010-00002","article-title":"Neurotensin agonists: Potential in the treatment of schizophrenia","volume":"21","author":"Boules","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0125","doi-asserted-by":"crossref","first-page":"E1008","DOI":"10.1152\/ajpendo.00345.2015","article-title":"Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice","volume":"309","author":"Boylan","year":"2015","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/03009734.2016.1156789","article-title":"Glucagon secretion from pancreatic alpha-cells","volume":"121","author":"Briant","year":"2016","journal-title":"Upsala Journal of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0135","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1210\/en.2018-00311","article-title":"Lateral hypothalamic area neurotensin neurons are required for control of orexin neurons and energy balance","volume":"159","author":"Brown","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0140","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2016.10.046","article-title":"The vagus nerve in appetite regulation, mood, and intestinal inflammation","volume":"152","author":"Browning","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.yhbeh.2012.04.010","article-title":"Leptin, a neuroendocrine mediator of immune responses, inflammation, and sickness behaviors","volume":"62","author":"Carlton","year":"2012","journal-title":"Hormones and Behavior"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41366-020-00711-3","article-title":"Gastric ghrelin cells in obese patients are hyperactive","volume":"45","author":"Castorina","year":"2021","journal-title":"International Journal of Obesity"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0014-4800(84)90049-2","article-title":"Suppression of weight gain by glucagon in obese Zucker rats","volume":"40","author":"Chan","year":"1984","journal-title":"Experimental and Molecular Pathology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0160","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1210\/jc.2014-4024","article-title":"RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals","volume":"100","author":"Chen","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0165","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40265-013-0074-7","article-title":"Metreleptin: First global approval","volume":"73","author":"Chou","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0170","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: Single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Clement","year":"2020","journal-title":"The Lancet Diabetes and Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0175","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2337\/db13-1609","article-title":"GLP-1\/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet","volume":"63","author":"Clemmensen","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00125-006-0481-3","article-title":"Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia","volume":"50","author":"Conarello","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0185","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/psc.2727","article-title":"Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake","volume":"21","author":"Dalboge","year":"2015","journal-title":"Journal of Peptide Science"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.yfrne.2010.06.002","article-title":"Leptin in human physiology and therapeutics","volume":"31","author":"Dardeno","year":"2010","journal-title":"Frontiers in Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0205","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1210\/endo.141.11.7757","article-title":"Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans","volume":"141","author":"Date","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0210","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/gast.2002.35954","article-title":"The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats","volume":"123","author":"Date","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0215","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cmet.2006.09.004","article-title":"Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus","volume":"4","author":"Date","year":"2006","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0220","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/1801124a0","article-title":"Calorigenic action of glucagon","volume":"180","author":"Davidson","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0225","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0230","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0235","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/0024-3205(82)90614-2","article-title":"Modified metabolic responsiveness to glucagon in cold-acclimated and heat-acclimated rats","volume":"30","author":"Doi","year":"1982","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0240","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/nm.4432","article-title":"Asprosin is a centrally acting orexigenic hormone","volume":"23","author":"Duerrschmid","year":"2017","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0245","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0303-7207(98)00096-3","article-title":"Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression","volume":"141","author":"Dunphy","year":"1998","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0250","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0255","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0260","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.bbrc.2017.08.084","article-title":"Neuromedin U precursor-related peptide (NURP) exerts neuromedin U-like sympathetic nerve action in the rat","volume":"492","author":"Ensho","year":"2017","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0265","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/385165a0","article-title":"Role of melanocortinergic neurons in feeding and the agouti obesity syndrome","volume":"385","author":"Fan","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0270","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neulet.2006.05.034","article-title":"Chemical genetic analysis reveals the effects of NMU2R on the expression of peptide hormones","volume":"404","author":"Fang","year":"2006","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0275","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pbb.2004.12.005","article-title":"Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys","volume":"80","author":"Fantegrossi","year":"2005","journal-title":"Pharmacology, Biochemistry and Behavior"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0280","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2009.07.001","article-title":"The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature","volume":"58","author":"Feifel","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0285","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ceca.2014.08.011","article-title":"Human IAPP amyloidogenic properties and pancreatic beta-cell death","volume":"56","author":"Fernandez","year":"2014","journal-title":"Cell Calcium"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0300","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1530\/EJE-19-0684","article-title":"Plasma levels of ghrelin, des-acyl ghrelin and LEAP2 in children with obesity: Correlation with age and insulin resistance","volume":"182","author":"Fittipaldi","year":"2020","journal-title":"European Journal of Endocrinology of the European Federation of Endocrine Societies"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0305","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5665\/sleep.1958","article-title":"Altered sleep and affect in the neurotensin receptor 1 knockout mouse","volume":"35","author":"Fitzpatrick","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0310","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003163","article-title":"Vaccination against GIP for the treatment of obesity","volume":"3","author":"Fulurija","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(05)24001-9","article-title":"Distribution, function, and properties of leptin receptors in the brain","volume":"224","author":"Funahashi","year":"2003","journal-title":"International Review of Cytology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0325","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1210\/jc.2017-02265","article-title":"Pramlintide but not liraglutide suppresses meal-stimulated glucagon responses in type 1 diabetes","volume":"103","author":"Galderisi","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0330","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","article-title":"Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: A multicenter, randomized, double-blind, crossover, pilot study","volume":"21","author":"Garcia","year":"2013","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0335","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cmet.2017.10.016","article-title":"LEAP2 is an endogenous antagonist of the ghrelin receptor","volume":"27","author":"Ge","year":"2018","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0340","first-page":"R116","article-title":"Glucagon acts in the liver to control spontaneous meal size in rats","volume":"264","author":"Geary","year":"1993","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0345","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1073\/pnas.0237106100","article-title":"Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice","volume":"100","author":"Gelling","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0350","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1210\/jcem.87.6.8739","article-title":"The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans","volume":"87","author":"Gnanapavan","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0355","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0006-8993(83)90576-0","article-title":"The regional distribution of neurotensin-like immunoreactivity in central and peripheral tissues of the cat","volume":"272","author":"Goedert","year":"1983","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0360","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1073\/pnas.0800708105","article-title":"Ghrelin octanoylation mediated by an orphan lipid transferase","volume":"105","author":"Gutierrez","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0365","first-page":"R1541","article-title":"Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2","volume":"276","author":"Gutzwiller","year":"1999","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0370","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db12-1116","article-title":"Fibroblast growth factor 21 mediates specific glucagon actions","volume":"62","author":"Habegger","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0375","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.mayocp.2017.12.003","article-title":"The role of glucagon in the pathophysiology and treatment of type 2 diabetes","volume":"93","author":"Haedersdal","year":"2018","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0380","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1210\/clinem\/dgaa803","article-title":"Identification and metabolic profiling of a novel human gut-derived LEAP2 fragment","volume":"106","author":"Hagemann","year":"2021","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0385","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1210\/jc.2006-1442","article-title":"Association between neuromedin U gene variants and overweight and obesity","volume":"91","author":"Hainerova","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0390","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.7624777","article-title":"Weight-reducing effects of the plasma protein encoded by the obese gene","volume":"269","author":"Halaas","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0395","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nm1106","article-title":"Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway","volume":"10","author":"Hanada","year":"2004","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0400","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bbrc.2003.10.098","article-title":"Central actions of neuromedin U via corticotropin-releasing hormone","volume":"311","author":"Hanada","year":"2003","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0405","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000177467","article-title":"Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes","volume":"32","author":"Hauner","year":"1988","journal-title":"Annals of Nutrition and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0410","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/0091-3057(86)90170-X","article-title":"Synergistic effects of dopamine agonists and centrally administered neurotensin on feeding","volume":"24","author":"Hawkins","year":"1986","journal-title":"Pharmacology, Biochemistry and Behavior"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0415","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1210\/en.2008-1479","article-title":"Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling","volume":"150","author":"Hayes","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0420","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0425","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0430","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1073\/pnas.81.14.4368","article-title":"Identification of glucagon receptors in rat brain","volume":"81","author":"Hoosein","year":"1984","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0435","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3389\/fendo.2018.00442","article-title":"No guts, no loss: Toward the ideal treatment for obesity in the twenty-first century","volume":"9","author":"Hope","year":"2018","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0440","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1055\/s-0029-1211484","article-title":"Radioimmunoassay for the detection of leptin in human serum","volume":"104","author":"Horn","year":"1996","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0445","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/35017610","article-title":"Identification of receptors for neuromedin U and its role in feeding","volume":"406","author":"Howard","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0450","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0455","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1507\/endocrj.EJ18-0372","article-title":"Basal glucagon hypersecretion and response to oral glucose load in prediabetes and mild type 2 diabetes","volume":"66","author":"Ichikawa","year":"2019","journal-title":"Endocrine Journal"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0460","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.bmc.2012.06.003","article-title":"PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes","volume":"20","author":"Ingallinella","year":"2012","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0465","first-page":"R120","article-title":"Central action of glucagon in rat hypothalamus","volume":"250","author":"Inokuchi","year":"1986","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0470","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.bmc.2017.02.023","article-title":"A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects","volume":"25","author":"Inooka","year":"2017","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0475","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/JOE-19-0102","article-title":"Liver-expressed antimicrobial peptide 2 antagonizes the effect of ghrelin in rodents","volume":"244","author":"Islam","year":"2020","journal-title":"Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0480","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1210\/en.2002-220121","article-title":"Evaluation of neuromedin U actions in energy homeostasis and pituitary function","volume":"143","author":"Ivanov","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0485","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/ATVBAHA.116.307847","article-title":"Circulating proneurotensin concentrations and cardiovascular disease events in the community: The Framingham heart study","volume":"36","author":"Januzzi","year":"2016","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101088","article-title":"IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study","volume":"39","author":"Ji","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0495","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MPA.0b013e31818d9095","article-title":"Does somatostatin confer insulinostatic effects of neuromedin u in the rat pancreas?","volume":"38","author":"Kaczmarek","year":"2009","journal-title":"Pancreas"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0500","first-page":"951","article-title":"Neuromedin U receptor 1 expression in the rat endocrine pancreas and evidence suggesting neuromedin U suppressive effect on insulin secretion from isolated rat pancreatic islets","volume":"18","author":"Kaczmarek","year":"2006","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0505","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.peptides.2011.04.027","article-title":"Recent advances in the phylogenetic study of ghrelin","volume":"32","author":"Kaiya","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0510","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cbpa.2007.12.004","article-title":"Ghrelin: A multifunctional hormone in non-mammalian vertebrates","volume":"149","author":"Kaiya","year":"2008","journal-title":"Comparative Biochemistry and Physiology. Part A: Molecular and Integrative Physiology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0515","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1021\/acs.jmedchem.7b00330","article-title":"Potent body weight-lowering effect of a neuromedin U receptor 2-selective PEGylated peptide","volume":"60","author":"Kanematsu-Yamaki","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0520","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jdi.12464","article-title":"Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist","volume":"7","author":"Katsurada","year":"2016","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0525","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0530","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbr.2008.06.024","article-title":"Impaired anorectic effect of leptin in neurotensin receptor 1-deficient mice","volume":"194","author":"Kim","year":"2008","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0535","article-title":"GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0540","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1074\/jbc.M609088200","article-title":"Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade","volume":"282","author":"Kim","year":"2007","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0545","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1194\/jlr.M006841","article-title":"GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene","volume":"51","author":"Kim","year":"2010","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0550","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1210\/en.2014-1175","article-title":"Glucagon is essential for adaptive thermogenesis in brown adipose tissue","volume":"155","author":"Kinoshita","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0555","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.pupt.2008.05.001","article-title":"Ghrelin treatment suppresses neutrophil-dominant inflammation in airways of patients with chronic respiratory infection","volume":"21","author":"Kodama","year":"2008","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0560","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/bbrc.2000.3502","article-title":"Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3)","volume":"276","author":"Kojima","year":"2000","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0565","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0570","first-page":"881","article-title":"The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors","volume":"86","author":"Korbonits","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0575","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1677\/joe.1.05948","article-title":"Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice","volume":"185","author":"Kowalski","year":"2005","journal-title":"Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0580","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1110\/ps.0213603","article-title":"Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver","volume":"12","author":"Krause","year":"2003","journal-title":"Protein Science"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170342","article-title":"Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms","volume":"131","author":"Krieger","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0590","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/509","article-title":"Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans","volume":"19","author":"Krude","year":"1998","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0595","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0600","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cmet.2018.10.008","article-title":"Neuromedin U does not act as a decretin in rats","volume":"29","author":"Kuhre","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0605","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0610","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.2174\/138161212803216906","article-title":"The growth hormone secretagogue receptor (Ghs-R)","volume":"18","author":"Laviano","year":"2012","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0615","first-page":"R162","article-title":"Hepatic portal infusion of glucagon antibodies increases spontaneous meal size in rats","volume":"261","author":"Le Sauter","year":"1991","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0620","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/379632a0","article-title":"Abnormal splicing of the leptin receptor in diabetic mice","volume":"379","author":"Lee","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0625","doi-asserted-by":"crossref","first-page":"11848","DOI":"10.1073\/pnas.182420899","article-title":"PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue","volume":"99","author":"Lee","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0630","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.cmet.2021.04.019","article-title":"Neurotensin is an anti-thermogenic peptide produced by lymphatic endothelial cells","volume":"33","author":"Li","year":"2021","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0635","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nature17662","article-title":"An obligatory role for neurotensin in high-fat-diet-induced obesity","volume":"533","author":"Li","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0640","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cmet.2015.10.012","article-title":"Hypothalamic amylin acts in concert with leptin to regulate food intake","volume":"22","author":"Li","year":"2015","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0645","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cell.2019.03.044","article-title":"Human gain-of-function MC4R variants show signaling bias and protect against obesity","volume":"177","author":"Lotta","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100263","article-title":"GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys","volume":"2","author":"Lu","year":"2021","journal-title":"Cell Reports Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0655","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.713961","article-title":"Neuromedins NMU and NMS: An updated overview of their functions","volume":"12","author":"Malendowicz","year":"2021","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0660","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.mce.2011.06.006","article-title":"The Peptidic GHS-R antagonist [D-Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity","volume":"343","author":"Maletinska","year":"2011","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0665","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cmet.2008.03.007","article-title":"Ghrelin modulates brain activity in areas that control appetitive behavior","volume":"7","author":"Malik","year":"2008","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0670","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1172\/JCI125332","article-title":"LEAP2 changes with body mass and food intake in humans and mice","volume":"129","author":"Mani","year":"2019","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0675","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/sj.ijo.0802142","article-title":"Leptin: A review of its peripheral actions and interactions","volume":"26","author":"Margetic","year":"2002","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0680","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/dmrr.263","article-title":"Role of amylin in insulin secretion and action in humans: Antagonist studies across the spectrum of insulin sensitivity","volume":"18","author":"Mather","year":"2002","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0685","doi-asserted-by":"crossref","first-page":"E1746","DOI":"10.1152\/ajpendo.00460.2007","article-title":"GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet","volume":"293","author":"McClean","year":"2007","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0690","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00125-003-1103-y","article-title":"Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia","volume":"46","author":"Meier","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0695","doi-asserted-by":"crossref","first-page":"E621","DOI":"10.1152\/ajpendo.00499.2003","article-title":"Gastric inhibitory polypeptide does not inhibit gastric emptying in humans","volume":"286","author":"Meier","year":"2004","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0700","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/diabetes.50.11.2497","article-title":"Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes","volume":"50","author":"Meier","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0705","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.2012.12998","article-title":"Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality","volume":"308","author":"Melander","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0710","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0715","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","article-title":"Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease","volume":"27","author":"Mesnage","year":"2004","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108187_bib1261","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nm.3115","article-title":"Hypothalamic glucagon signaling inhibits hepatic glucose production.","volume":"19","author":"Mighiu","year":"2013","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0720","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0006-291X(88)80848-9","article-title":"Isolation and structural determination of rat neuromedin U","volume":"156","author":"Minamino","year":"1988","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0725","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/0006-291X(85)91726-7","article-title":"Neuromedin U-8 and U-25: Novel uterus stimulating and hypertensive peptides identified in porcine spinal cord","volume":"130","author":"Minamino","year":"1985","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0730","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1476-5381.2009.00252.x","article-title":"Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S","volume":"158","author":"Mitchell","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0735","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2337\/diab.39.5.639","article-title":"Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration","volume":"39","author":"Mitsukawa","year":"1990","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0740","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1007\/s00216-017-0534-0","article-title":"Accurate analytical method for human plasma glucagon levels using liquid chromatography-high resolution mass spectrometry: Comparison with commercially available immunoassays","volume":"409","author":"Miyachi","year":"2017","journal-title":"Analytical and Bioanalytical Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0745","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0750","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1021\/acs.jmedchem.8b01644","article-title":"N-terminal liver-expressed antimicrobial peptide 2 (LEAP2) region exhibits inverse agonist activity toward the ghrelin receptor","volume":"62","author":"M\u2019Kadmi","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0755","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/43185","article-title":"Congenital leptin deficiency is associated with severe early-onset obesity in humans","volume":"387","author":"Montague","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0760","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1210\/er.2012-1053","article-title":"Leptin\u2019s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals","volume":"34","author":"Moon","year":"2013","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0765","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2337\/db14-0625","article-title":"Identification and saturable nature of signaling pathways induced by metreleptin in humans: Comparative evaluation of in vivo, ex vivo, and in vitro administration","volume":"64","author":"Moon","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0770","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/db10-1791","article-title":"Efficacy of metreleptin in obese patients with type 2 diabetes: Cellular and molecular pathways underlying leptin tolerance","volume":"60","author":"Moon","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0775","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/000456327801500138","article-title":"Radioimmunoassay of gastric inhibitory polypeptide","volume":"15","author":"Morgan","year":"1978","journal-title":"Annals of Clinical Biochemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0780","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10319-9","article-title":"Identification of neuromedin U precursor-related peptide and its possible role in the regulation of prolactin release","volume":"7","author":"Mori","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0785","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature21697","article-title":"MC4R-dependent suppression of appetite by bone-derived lipocalin 2","volume":"543","author":"Mosialou","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0790","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1210\/endo.140.6.6930","article-title":"An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3","volume":"140","author":"Muff","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0795","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0800","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bph.14077","article-title":"Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice","volume":"175","author":"Nagai","year":"2018","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0805","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: A 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0810","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-64-5-896","article-title":"Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency","volume":"64","author":"Nair","year":"1987","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0815","first-page":"E808","article-title":"Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1","volume":"271","author":"Nakabayashi","year":"1996","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0820","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bbrc.2019.10.156","article-title":"Neuromedin U suppresses prolactin secretion via dopamine neurons of the arcuate nucleus","volume":"521","author":"Nakahara","year":"2020","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0825","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/278423a0","article-title":"Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor","volume":"278","author":"Nakanishi","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0830","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/bbrc.2000.3669","article-title":"Central effects of neuromedin U in the regulation of energy homeostasis","volume":"277","author":"Nakazato","year":"2000","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0835","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0006-291X(90)90389-5","article-title":"Islet amyloid polypeptide, a novel pancreatic peptide, is a circulating hormone secreted under glucose stimulation","volume":"169","author":"Nakazato","year":"1990","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0840","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35051587","article-title":"A role for ghrelin in the central regulation of feeding","volume":"409","author":"Nakazato","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0845","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0850","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0855","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/psc.2582","article-title":"Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide","volume":"20","author":"Neuner","year":"2014","journal-title":"Journal of Peptide Science"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0860","doi-asserted-by":"crossref","first-page":"e3483","DOI":"10.1210\/clinem\/dgab355","article-title":"Pro-neurotensin\/neuromedin N and risk of incident metabolic syndrome and diabetes mellitus in the REGARDS cohort","volume":"106","author":"Nicoli","year":"2021","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0865","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/ENDO:16:3:201","article-title":"Central administration of neuromedin U activates neurons in ventrobasal hypothalamus and brainstem","volume":"16","author":"Niimi","year":"2001","journal-title":"Endocrine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0870","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dom.13034","article-title":"A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents","volume":"20","author":"Norregaard","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0875","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2826.2006.01454.x","article-title":"Neuromedin U in the paraventricular and arcuate hypothalamic nuclei increases non-exercise activity thermogenesis","volume":"18","author":"Novak","year":"2006","journal-title":"Journal of Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0880","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/0006-291X(90)90524-Q","article-title":"Islet amyloid polypeptide (IAPP) does not inhibit glucose-stimulated insulin secretion from isolated perfused rat pancreas","volume":"170","author":"O\u2019Brien","year":"1990","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0885","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0006-291X(89)92529-1","article-title":"Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets","volume":"160","author":"Ohsawa","year":"1989","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0890","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22361-3","article-title":"Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia","volume":"12","author":"Olson","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0895","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1084\/jem.5.5.527","article-title":"The relation oe diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands oe Langerhans","volume":"5","author":"Opie","year":"1901","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0900","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.molmet.2013.07.008","article-title":"Loss of neurotensin receptor-1 disrupts the control of the mesolimbic dopamine system by leptin and promotes hedonic feeding and obesity","volume":"2","author":"Opland","year":"2013","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0905","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0910","doi-asserted-by":"crossref","first-page":"7745","DOI":"10.4049\/jimmunol.176.12.7745","article-title":"Leptin receptor expression and signaling in lymphocytes: Kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice","volume":"176","author":"Papathanassoglou","year":"2006","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0915","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1210\/en.2010-1463","article-title":"Effects of peripherally administered neuromedin U on energy and glucose homeostasis","volume":"152","author":"Peier","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0920","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1126\/science.7624776","article-title":"Effects of the obese gene product on body weight regulation in ob\/ob mice","volume":"269","author":"Pelleymounter","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108639","article-title":"Activation of ventral tegmental area neurotensin receptor-1 neurons promotes weight loss","volume":"195","author":"Perez-Bonilla","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0930","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0935","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00592-020-01483-y","article-title":"Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: Systematic review and meta-analysis","volume":"57","author":"Pontiroli","year":"2020","journal-title":"Acta Diabetologica"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0940","doi-asserted-by":"crossref","first-page":"66504","DOI":"10.18632\/oncotarget.16008","article-title":"Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: A systematic review and meta-analysis","volume":"8","author":"Qiao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0945","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.molmet.2015.09.014","article-title":"Hypothalamic CaMKKbeta mediates glucagon anorectic effect and its diet-induced resistance","volume":"4","author":"Quinones","year":"2015","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0950","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/db18-1009","article-title":"Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway","volume":"68","author":"Ratner","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0955","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab130","article-title":"Anorexia and fat aversion induced by vertical sleeve gastrectomy is attenuated in neurotensin receptor 1-deficient mice","volume":"162","author":"Ratner","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0960","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1210\/en.2016-1329","article-title":"Effects of peripheral neurotensin on appetite regulation and its role in gastric bypass surgery","volume":"157","author":"Ratner","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0965","doi-asserted-by":"crossref","first-page":"21432","DOI":"10.1016\/S0021-9258(19)36628-1","article-title":"Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4","volume":"267","author":"Raufman","year":"1992","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0970","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintide\/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0975","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0014-2999(81)90469-6","article-title":"The hypotensive effect of centrally administered neurotensin in rats","volume":"69","author":"Rioux","year":"1981","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0980","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cmet.2017.09.021","article-title":"Overlapping brain circuits for homeostatic and hedonic feeding","volume":"27","author":"Rossi","year":"2018","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0985","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.0706473105","article-title":"Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies","volume":"105","author":"Roth","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0990","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2826.1995.tb00673.x","article-title":"Stimulation of CRH-mediated ACTH secretion by central administration of neurotensin: Evidence for the participation of the paraventricular nucleus","volume":"7","author":"Rowe","year":"1995","journal-title":"Journal of Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb0995","first-page":"255","article-title":"Expression of neuromedins S and U and their receptors in the hypothalamus and endocrine glands of the rat","volume":"20","author":"Rucinski","year":"2007","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1000","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2111","article-title":"Human liver-expressed antimicrobial peptide 2 elevation in the cerebrospinal fluid in bacterial meningitis","volume":"11","author":"Sakai","year":"2021","journal-title":"Brain and Behavior: A Cognitive Neuroscience Perspective"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0304-3940(03)00294-5","article-title":"Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglion","volume":"342","author":"Sakata","year":"2003","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/dom.12585","article-title":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans","volume":"18","author":"Salem","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/cne.902980206","article-title":"Distribution of neurotensin-containing fibers in the frontal cortex of the macaque monkey","volume":"298","author":"Satoh","year":"1990","journal-title":"Journal of Comparative Neurology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1020","first-page":"397","article-title":"Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: Methodological aspects and clinical applications","volume":"22","author":"Scheen","year":"1996","journal-title":"Diabetes & Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1025","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/dom.14394","article-title":"Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1\/glucagon receptor agonist SAR425899 in comparison with liraglutide","volume":"23","author":"Schiavon","year":"2021","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1030","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.2337\/diabetes.53.2007.S152","article-title":"Leptin effects on pancreatic beta-cell gene expression and function","volume":"53","author":"Seufert","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2337\/dc15-1606","article-title":"Glucagon nasal powder: A promising alternative to intramuscular glucagon in youth with type 1 diabetes","volume":"39","author":"Sherr","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1530\/EJE-11-0252","article-title":"Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet","volume":"165","author":"Shetty","year":"2011","journal-title":"European Journal of Endocrinology of the European Federation of Endocrine Societies"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1210\/jcem.87.1.8129","article-title":"Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion","volume":"87","author":"Shiiya","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2337\/dc12-1128","article-title":"Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: Pharmacokinetics and pharmacodynamics","volume":"36","author":"Shin","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1055","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1463-1326.2010.01337.x","article-title":"The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: A systematic review and meta-analysis","volume":"13","author":"Singh-Franco","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1060","doi-asserted-by":"crossref","first-page":"E620","DOI":"10.1152\/ajpendo.00217.2007","article-title":"Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: A 6-wk translational research study","volume":"293","author":"Smith","year":"2007","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0303-7207(94)90162-7","article-title":"Relative quantitative analysis of glucagon receptor mRNA in rat tissues","volume":"105","author":"Svoboda","year":"1994","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1070","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1210\/jcem.85.12.7167","article-title":"Ghrelin strongly stimulates growth hormone release in humans","volume":"85","author":"Takaya","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115454","article-title":"A chemically stable peptide agonist to neuromedin U receptor type 2","volume":"28","author":"Takayama","year":"2020","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1080","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00595-015-1187-2","article-title":"Impact of synthetic ghrelin administration for patients with severe body weight reduction more than 1 year after gastrectomy: A phase II clinical trial","volume":"46","author":"Takiguchi","year":"2016","journal-title":"Surgery Today"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1085","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/01.HYP.0000175474.99326.bf","article-title":"Melanocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia","volume":"46","author":"Tallam","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/acs.molpharmaceut.9b00571","article-title":"Transnasal delivery of the peptide agonist specific to neuromedin-U receptor 2 to the brain for the treatment of obesity","volume":"17","author":"Tanaka","year":"2020","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1095","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1074\/jbc.272.10.6093","article-title":"The leptin receptor","volume":"272","author":"Tartaglia","year":"1997","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1100","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0092-8674(95)90151-5","article-title":"Identification and expression cloning of a leptin receptor, OB-R","volume":"83","author":"Tartaglia","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084238","article-title":"Neuromedin U, a key molecule in metabolic disorders","volume":"22","author":"Teranishi","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1530\/EJE-20-0087","article-title":"Pro-neurotensin depends on renal function and is related to all-cause mortality in chronic kidney disease","volume":"183","author":"Tonjes","year":"2020","journal-title":"European Journal of Endocrinology of the European Federation of Endocrine Societies"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1120","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2468-1253(17)30147-4","article-title":"The microbiota-gut-brain axis in obesity","volume":"2","author":"Torres-Fuentes","year":"2017","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1125","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1210\/en.2005-1357","article-title":"Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor","volume":"147","author":"Toshinai","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1130","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/35038090","article-title":"Ghrelin induces adiposity in rodents","volume":"407","author":"Tsch\u00f6p","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2016.06.021","article-title":"Unimolecular polypharmacy for treatment of diabetes and obesity","volume":"24","author":"Tsch\u00f6p","year":"2016","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41588-017-0011-x","article-title":"Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity","volume":"50","author":"Turcot","year":"2018","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1145","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.2337\/dc13-0690","article-title":"Exploratory trial of intranasal administration of glucagon-like peptide-1 in Japanese patients with type 2 diabetes","volume":"37","author":"Ueno","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1150","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13300-018-0366-8","article-title":"Effects of ipragliflozin on postprandial glucose metabolism and gut peptides in type 2 diabetes: A pilot study","volume":"9","author":"Ueno","year":"2018","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1155","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1507\/endocrj.K07-007","article-title":"Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics","volume":"54","author":"Ueno","year":"2007","journal-title":"Endocrine Journal"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0006-8993(79)90264-6","article-title":"Neurotensin-containing cell bodies, fibers and nerve terminals in the brain stem of the rat: Immunohistochemical mapping","volume":"167","author":"Uhl","year":"1979","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1165","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1007\/s12035-018-1362-8","article-title":"Evidence Supporting a Role for the Blood-Cerebrospinal Fluid Barrier Transporting Circulating Ghrelin into the Brain","volume":"56","author":"Uriarte","year":"2019","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1170","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/dom.14110","article-title":"The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists","volume":"22","author":"Urva","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1175","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1180","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.neuropharm.2014.05.046","article-title":"Activation of neurotensin receptor type 1 attenuates locomotor activity","volume":"85","author":"Vadnie","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1185","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc16-1553","article-title":"Efficacy and safety of metreleptin therapy in patients with type 1 diabetes: A pilot study","volume":"40","author":"Vasandani","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1190","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients","volume":"45","author":"Vilsboll","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1195","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-6147(99)01357-7","article-title":"Neurotensin and neurotensin receptors","volume":"20","author":"Vincent","year":"1999","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1200","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/febs.14763","article-title":"Identifying the binding mechanism of LEAP2 to receptor GHSR1a","volume":"286","author":"Wang","year":"2019","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1205","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0031-9384(88)90220-X","article-title":"Lesion of vagal afferent terminals impairs glucagon-induced suppression of food intake","volume":"43","author":"Weatherford","year":"1988","journal-title":"Physiology and Behavior"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/03009734.2011.573884","article-title":"Amyloid in the islets of Langerhans: Thoughts and some historical aspects","volume":"116","author":"Westermark","year":"2011","journal-title":"Upsala Journal of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1215","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1073\/pnas.84.11.3881","article-title":"Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells","volume":"84","author":"Westermark","year":"1987","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1220","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.2337\/diabetes.50.11.2540","article-title":"Ghrelin causes hyperphagia and obesity in rats","volume":"50","author":"Wren","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1225","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1210\/en.2002-220308","article-title":"Hypothalamic actions of neuromedin U","volume":"143","author":"Wren","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1230","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.2337\/db07-0007","article-title":"The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance","volume":"56","author":"Yan","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1235","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2008.01.017","article-title":"Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone","volume":"132","author":"Yang","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1240","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1245","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bbrc.2017.08.132","article-title":"Neuromedin U suppresses glucose-stimulated insulin secretion in pancreatic beta cells","volume":"493","author":"Zhang","year":"2017","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1250","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1096\/fj.201901743R","article-title":"Neuromedin U suppresses insulin secretion by triggering mitochondrial dysfunction and endoplasmic reticulum stress in pancreatic beta-cells","volume":"34","author":"Zhang","year":"2020","journal-title":"FASEB Journal"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1255","article-title":"Neuromedin U uses Galphai2 and Galphao to suppress glucose-stimulated Ca2+ signaling and insulin secretion in pancreatic beta cells","volume":"16","author":"Zhang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108187_bb1260","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11684-013-0263-5","article-title":"Leptin signaling and leptin resistance","volume":"7","author":"Zhou","year":"2013","journal-title":"Frontiers of Medicine"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582200081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582200081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:22:48Z","timestamp":1759011768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582200081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":253,"alternative-id":["S016372582200081X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108187","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulation of feeding and therapeutic application of bioactive peptides","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108187"}}